Ani Pharmaceuticals (ANIP) Operating Expenses (2016 - 2025)
Ani Pharmaceuticals (ANIP) has disclosed Operating Expenses for 16 consecutive years, with $212.3 million as the latest value for Q4 2025.
- Quarterly Operating Expenses rose 8.9% to $212.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $772.3 million through Dec 2025, up 25.82% year-over-year, with the annual reading at $772.3 million for FY2025, 25.82% up from the prior year.
- Operating Expenses hit $212.3 million in Q4 2025 for Ani Pharmaceuticals, up from $191.6 million in the prior quarter.
- In the past five years, Operating Expenses ranged from a high of $212.3 million in Q4 2025 to a low of $51.5 million in Q1 2021.
- Historically, Operating Expenses has averaged $121.7 million across 5 years, with a median of $109.0 million in 2023.
- Biggest five-year swings in Operating Expenses: decreased 10.66% in 2021 and later skyrocketed 62.55% in 2022.
- Year by year, Operating Expenses stood at $84.7 million in 2021, then rose by 9.17% to $92.4 million in 2022, then surged by 35.19% to $124.9 million in 2023, then surged by 56.05% to $195.0 million in 2024, then increased by 8.9% to $212.3 million in 2025.
- Business Quant data shows Operating Expenses for ANIP at $212.3 million in Q4 2025, $191.6 million in Q3 2025, and $197.5 million in Q2 2025.